Tag Archives: genomic assay

Colorectal Cancer Molecules and Genes Reveal Surprises

A Labor Day salute to the hard-working scientists—doctors, PhDs, lab techs, technology inventors—who have done some  heavy lifting to peer into the tiniest recesses of cells, genes, and molecules to unravel what makes colorectal cancer happen. In the widest and deepest effort to date, the Cancer Genome Atlas Project has produced some surprises and key clues about colorectal cancer, published recently in the journal Nature. It was almost “ industrial-strength genetics to try to unpick and take apart the genetic coding,” according to Dr. David Kerr, professor at the University of Oxford and Past President of the European Society for Medical Oncology.  One of the surprises for colorectal cancer—the third

Leading GI Cancer Researcher Updates Patients

Last night, Dr. Edith Mitchell of Thomas Jefferson University Kimmel Cancer Center in Philadelphia, PA, updated colorectal cancer patients on the latest research and treatment news in an online webinar. Dr. Mitchell highlighted the most important news for colon and rectal cancer patients to come from the 2011 Gastrointestinal Cancers Symposium held in San Francisco last month. She answer such questions as… “Can doctors determine the chances that my cancer may return?” “Can my doctors determine if I need chemotherapy?” “Does Avastin or Erbitux benefit my stage III cancer treatment?” “Are there any promising new treatments on the horizon?”

Gene Test Shows Risk of Recurrence of Stage II Colon Cancer

The first genomic test to predict whether or not stage II colon cancer will recur has been developed and validated in a large number of tumor tissue samples from patients in the United States and the United Kingdom.  The 12 gene assay can reliably predict whether an individual patient has a low, intermediate, or high risk of having their cancer return. Doctors and patients will be able to use the Recurrence Score, along with other clinical indicators, to decide whether further chemotherapy treatment after surgery should be considered or whether they can safely skip chemo and its risks. However, the study was not able to link recurrence scores with benefits

Top